Today we will discuss a set of three articles on Johnson & Johnson (JNJ), each of which makes a numbers analysis of the company and some of which, at least, suggests taking profit. These articles are by Josh Arnold, DoctoRx and Nicholas Ward. While Josh Arnold thinks that JNJ's latest earnings numbers are "beautiful" but the company is now overbought, DoctoRx thinks that the numbers look "all prettied up" with non-GAAP exclusions that should, if taken, make the EPS actually look even worse than the 10.5% yoy decline seen under GAAP.

Nicholas Ward, coming from another front, thinks JNJ's slowing dividend growth makes it a prime target for profit taking. Of these, the DoctoRx article explains JNJ numbers so lucidly that it even made sense to the most numerically handicapped among us.

READ FULL ARTICLE HERE